In addition, the writing committee unanimously feels it important to include new harmoniz- ing measures for stage 1 HBP and a composite measure (ie, for ACC/AHA stage 2 and ACC/AHA stage 1 com- bined) that emphasize the importance of controlling HBP below the new ACC/AHA target of 130/80 mmHg, as recommended by the 2017 Hypertension Clinical Practice Because of the importance of the promo- tion of intensive nonpharmacological healthy lifestyle modifications and home BP monitoring for patients with stage 2 HBP (as emphasized in the 2017 Hypertension Clinical Practice Guidelines,4 new performance measures to assess quality of care in this regard have been included. These new performance measures are also intended to harmonize with the performance measure for stage 2 HBP currently in use by CMS and NCQA. Quality measures, on the other hand, are intended to be deployed in collaborative quality improvement initia- tives (such as those promoted by the ACC and AHA) that do not require the degrees of technical rigor required for performance measures. The writing committee decided to include 6 new process quality measures based on Class 1 recommendations from the 2017 Hypertension Clini- cal Practice Guidelines4 recommendations that address important gaps in care for patients with HBP. If additional evidence evolves that demonstrates significant impact on the quality of care and meets NQF requirements for reliability, feasibility, usability, validity, and acceptable burden of data collection for these measures, then they may be considered as potential future performance mea- sures by the writing committee and other entities, such as CMS, NCQA, state Medicaid agencies, and NQF. Given the extensive emphasis on developing more effective systems of care for patients with HBP, the writ- ing committee also feels it is important to present a new concept of structural measures, which are designed to improve these systems. 